



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁴ : C07C X	A2	(11) International Publication Number: WO 88/ 09780 (43) International Publication Date: 15 December 1988 (15.12.88)
(21) International Application Number: PCT/US88/01947 (22) International Filing Date: 9 June 1988 (09.06.88) (31) Priority Application Number: 060,877 (32) Priority Date: 12 June 1987 (12.06.87) (33) Priority Country: US (71) Applicant: EASTMAN KODAK COMPANY [US/US]; 343 State Street, Rochester, NY 14650 (US). (72) Inventors: BOWERS, Cyril, Yarling ; 484 Audubon Street, New Orleans, LA 70118 (US). MOMANY, Frank, Alden ; 1-1 Concord Green, Concord, MA 02154 (US). CHANG, Ching, Hsong ; 16 Robin Drive, Fanwood, NJ 07023 (US). CODY, Wayne, Li- vingston ; RD 2, Box 65, Ringoes, NJ 08551 (US). HUBBS, John, Clark ; Rt. 10, Box 354, Kingsport, TN 37664 (US). FOSTER, Charles, Howard ; 1413 Do- byns Drive, Kingsport, TN 37664 (US).		(74) Agent: REITER, Stephen, E.; 343 State Street, Roches- ter, NY 14650 (US). (81) Designated States: AT (European patent), AU, BE (Eu- ropean patent), BR, CH (European patent), DE (Eu- ropean patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, NL (European patent), NO, SE (European patent), SU. Published <i>Without international search report and to be repu- blished upon receipt of that report.</i>
(54) Title: POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY (57) Abstract Disclosed are novel polypeptide compounds which promote the release and elevation of growth hormone levels in the blood of animals. Also disclosed are methods of promoting the release and elevation of growth hormone levels in the blood of animals using the disclosed polypeptide compounds.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

- 1 -

DescriptionPolypeptide Compounds Having Growth Hormone
Releasing Activity

This invention relates to novel polypeptide
5 compounds which promote the release of growth hormone
when administered to animals. In another aspect,
this invention relates to methods for promoting the
release and elevation of growth hormone levels in
animals by administration of specified growth hormone
10 releasing polypeptide compounds thereto.

Background of the Invention

It has been established in the scientific
literature that the elevation of growth hormone
levels in mammals upon administration of GH-releasing
15 compounds can lead to enhanced body weight and to
enhanced milk production if sufficiently elevated GH
levels occur upon administration (c.f., P. K. Baker,
et al., J. Animal Science 59 (supplement 1), 220
(1984); W. J. Croom et al., J. Dairy Sci. 67 (supple-
20 ment 1), 109 (1984); S. N. McCutcheon et al., J.
Dairy Sci. 67, 2881 (1984)). Further, it is known
that the elevation of growth hormone levels in
mammals can be accomplished by application of known
growth hormone releasing agents, such as the
25 naturally occurring growth hormone releasing hormones
disclosed by P. Brazeau et al., Proc. Natl. Acad.
Sci. 79, 7909 (1982), and M. O. Thorner et al.,
Lancet 1,24 (1983)).

The elevation of growth hormone levels in mammals
30 can also be accomplished by application of growth
hormone releasing peptides (GRP's), some of which
have been previously described (c.f. C. Y. Bowers et
al., Endocrinology 114, 1537 (1984), F. A.

- 2 -

Momany et al., Endocrinology 114, 1531 (1984) and C. Y. Bowers, 7th International Congress of Endocrinology Abstracts, 464 (1984)).

Antibodies to the endogenous growth hormone release inhibitor, somatostatin (SRIF) are also used to elevate GH levels. In the last case, growth hormone levels are elevated by removing the endogenous GH-release inhibitor (SRIF) before it reaches the pituitary, where it inhibits the release of GH (c.f. W. B. Wehrenberg et al., Endocrinology 115, 1218 (1984)).

Finally, it has been shown that some compounds such as morphine (c.f. C. Rivier et al., Endocrinology 100, 238 (1977)) and other alkaloids (c.f. C. Y. Bowers, Endocrinology 117, 1441 (1985)) and DAla², DLeu⁵-enkephalinamide (c.f. E. L. Lien et al., FEBS Letters 88, 208 (1978)) also release growth hormone by acting on the hypothalamus.

Objects of the Invention

It is an object of the present invention to provide novel growth hormone releasing compounds which are capable of promoting the release and elevation of growth hormone levels in the blood of animals.

It is another object of the present invention to provide methods for promoting the release and/or elevation of growth hormone levels in the blood of animals.

These and other objects of the present invention will become apparent from inspection of the following description and claims.

Statement of the Invention

In accordance with the present invention, we have discovered several novel polypeptide compounds which

- 3 -

promote the release of growth hormone in animals.
The novel polypeptide compounds of the present
invention have from seven up to eleven amino acid
residues each. The preparation, characterization and
5 administration of these novel growth hormone releas-
ing compounds will now be described in greater
detail.

Detailed Description of the Invention

The present invention is based on the discovery
10 of several short chain (i.e., seven up to eleven
amino acid residues) polypeptides which promote the
release and elevation of growth hormone level in the
blood of animals. The polypeptides contemplated to
be within the scope of the present invention are
15 defined by the following generic structure:



wherein X is selected from the group consisting of H,
DOPA, Lys, Phe, Tyr, Cys, Tyr-DAla-Phe-Gly,
Tyr-DAla-Gly-Phe and Tyr-Ala-Gly-Thr;

20 AA1 is selected from the group consisting of all
naturally occurring L-amino acids, as well as Met(O),
DOPA and Abu;

AA2 is selected from the group consisting of His
and 3(NMe)+His (i.e., wherein the imidazole ring is
25 methylated at the 3-position);

AA3 is selected from the group consisting of
DTrp, 5-fluoro-D or D/LTrp; 6-fluoro-D or D/LTrp
(i.e., wherein the indole ring is fluorinated at the
5- or 6-position), (formyl)DTrp (i.e., DTrp which is

- 4 -

formylated at the indole nitrogen), and *XTrp, wherein *XTrp is selected from the group consisting of the N-monomethylated DTrp isomers (i.e., (N^αMe)DTrp and (indole NMe)DTrp);

5 AA4 is selected from the group consisting of Ala, Gly and Ser;

AA6 is selected from the group consisting of DPhe and (NMe)DPhe;

AA7 is selected from the group consisting of Arg,
10 iLys, Lys and Orn; and

Z represents the C terminal end group of said polypeptide or the C terminal amino acid(s) plus end group, wherein Z is selected from the group consisting of -CONH₂, -COOH, -COOR, -CONHR, -CONR₂,
15 -CH₂OH and -CH₂OR, wherein R is an alkyl group having 1-6 carbon atoms or an aromatic ring having up to 12 carbon atoms; and wherein Z is alternatively selected from the group consisting of -Gly-Z', -Met-Z', -Lys-Z', -Cys-Z' (note that when a Cys
20 moiety is also present in the 1 position of the polypeptide (i.e., X or AA1 is Cys), the resulting peptide can exist in the linear form or in the cyclic form), -Gly-Tyr-Z', and -Ala-Tyr-Z', wherein Z' is selected from the group consisting of -CONH₂,
25 -CONHR, -COOH, -COOR, -CONR₂, -CH₂OH, and -CH₂OR, wherein R is as defined above;

and organic or inorganic addition salts of any of said polypeptides;

- 5 -

wherein the amino acid residue abbreviations used are in accordance with the standard peptide nomenclature:

	Gly	= Glycine
5	Tyr	= L-Tyrosine
	Ile	= L-Isoleucine
	Glu	= L-Glutamic Acid
	Thr	= L-Threonine
	Phe	= L-Phenylalanine
10	Ala	= L-Alanine
	Lys	= L-Lysine
	Asp	= L-Aspartic Acid
	Cys	= L-Cysteine
	Arg	= L-Arginine
15	Gln	= L-Glutamine
	Pro	= L-Proline
	Leu	= L-Leucine
	Met	= L-Methionine
	Ser	= L-Serine
20	Asn	= L-Asparagine
	His	= L-Histidine
	Trp	= L-Tryptophan
	Val	= L-Valine
	DOPA	= 3,4-L-Dihydroxyphenylalanine
25	Met(O)	= L-Methionine sulfoxide
	iLys	= N ^c -Isopropyl-L-lysine
	Abu	= alpha-L-Aminobutyric acid
	Orn	= L-Ornithine
	Pal	= 3-Pyridyl-L-alanine
30	Pgl	= L-Phenylglycine
	(beta)Ala	= beta alanine (i.e., 3-amino-propanoic acid)

All three letter amino acid abbreviations preceded by a "D" indicate the D-configuration of the amino acid residue.

- 6 -

The flexibility associated with the choice of basic, neutral or acidic amino acid residues for amino acid AA1 provides one with a great deal of control over the physiochemical properties of the
5 desired peptide. Such flexibility provides important advantages for the formulation and delivery of the desired peptide to any given species. Additional flexibility can be imparted by the fact that other amino acids (e.g., AA2, AA3, AA4, AA6, AA7) can be
10 varied, as well as the moieties R, X and Z, thereby providing added control over the physiochemical properties of the desired compound.

Preferred growth hormone releasing compound employed in the practice of the present invention are
15 selected from the group consisting of:

- Ala-His-DTrp-Ala-Trp-DPhe-Lys-Gly-Tyr-Z';
- Ala-His-(formyl)DTrp-Ala-Trp-DPhe-Lys-Z'
(DTrp is formylated at the indole
nitrogen);
- 20 Ala-His-DTrp-Ser-Trp-DPhe-Lys-Z';
- Cys-Ala-His-DTrp-Ala-Trp-DPhe-Lys-Cys-Z'
(cyclic disulfide);
- Cys-Ala-His-DTrp-Ala-Trp-DPhe-Lys-Cys-Z'
(free dithiol);
- 25 DOPA-Ala-His-DTrp-Ala-Trp-DPhe-Lys-Z';
- His-DTrp-Ala-Trp-DPhe-Lys-Ala-Tyr-Z';
- Lys-Ala-His-DTrp-Ala-Trp-DPhe-Lys-Z';
- Phe-Ala-His-DTrp-Ala-Trp-DPhe-Lys-Z';
- Tyr-Ala-Gly-Thr-Ala-His-DTrp-Ala-Trp-
30 DPhe-Lys-Z';
- Tyr-Ala-His-DTrp-Ala-Trp-DPhe-Lys-Z';
- Tyr-DAla-Phe-Gly-Ala-His-DTrp-Ala-Trp-DPhe-
Lys-Z';
- 35 Tyr-DAla-Gly-Phe-Ala-His-DTrp-Ala-Trp-DPhe-
Lys-Z';

- 7 -

Ala-His-DTrp-Ala-Trp-DPhe-iLys-Z';

Ala-His-DTrp-Ala-Trp-(NMe)DPhe-Lys-Z';

Ala-His-*XTrp*-Ala-Trp-DPhe-Lys-Z' (*XTrp*

5 is selected from the group consisting of
5-fluoro-D or D/LTrp; 6-fluoro-D or D/LTrp
(i.e., wherein the indole ring is
fluorinated at the 5- or 6-position), and
the N-monomethylated DTrp isomers, i.e.,
(N^αMe)DTrp, and (indole NMe)DTrp);

10 AAl-His-DTrp-Ala-Trp-DPhe-Lys-Z';

wherein AAl is selected from the group consisting of
all naturally occurring L-amino acids, as well as
Met(O), DOPA and Abu; and wherein Z' and R are as
defined above; and

15 organic or inorganic addition salts of any of
said polypeptides.

These compounds are preferred because of their
ease of synthesis, proven efficacy at promoting the
increase in serum growth hormone levels, and their
20 consequent appeal for commercial scale production and
utilization. In addition, these compounds may be
advantageous in having physiochemical properties
which are desirable for the efficient delivery of
such polypeptide compounds to a variety of animal
25 species. Because of the flexibility made possible by
the various substitutions at numerous positions of
the invention polypeptide compounds, a wide range of
delivery vehicles can be employed, by selecting the
polar, neutral or non-polar nature of the N-terminal,
30 C-terminal and center portions of these polypeptide
compounds so as to be compatible with the desired
method of delivery.

In a most preferred embodiment, growth hormone
releasing peptides employed in the practice of the
35 present invention are selected from the group
consisting of:

- 8 -

DOPA-Ala-His-DTrp-Ala-Trp-DPhe-Lys-Z";
His-DTrp-Ala-Trp-DPhe-Lys-Ala-Tyr-Z";
Lys-Ala-His-DTrp-Ala-Trp-DPhe-Lys-Z";
Tyr-Ala-His-DTrp-Ala-Trp-DPhe-Lys-Z";
5 Phe-Ala-His-DTrp-Ala-Trp-DPhe-Lys-Z";
Ala-His-DTrp-Ala-Trp-DPhe-iLys-Z";
Ala-His-DTrp-Ala-Trp-(NMe)DPhe-Lys-Z";
Ala-His-DTrp-Ala-Trp-DPhe-Lys (as the free
carboxylate);

10 AAl-His-DTrp-Ala-Trp-DPhe-Lys-Z";

wherein AAl is selected from the group consisting of
all naturally occurring L-amino acids, as well as
DOPA, Met(O) and Abu,

wherein Z" is $-\text{CONH}_2$, and

15 wherein organic or inorganic addition salts of
any of said polypeptides.

These compounds are the presently most preferred
because these shorter chain polypeptides are less
expensive to synthesize, and these specific compounds
20 have been shown to have a high level of potency at
promoting the increase in serum growth hormone
levels. In addition, these compounds have
advantageous physiochemical properties which allow
efficient transport of such polypeptides to the
25 receptor site for promotion of GH release. Note that
these compounds retain the flexibility to be altered
at both the N-terminal end and the C-terminal end, in
order to maximize the compatibility of the poly-
peptide compound with the species being treated and
30 the delivery vehicle being employed.

The compounds of this invention may be used to
enhance blood GH levels in animals; enhance milk
production in cows; enhance body growth in animals
such as mammals (e.g., humans, sheep, bovines, and
35 swine), as well as fish, fowl, other vertebrates and

- 9 -

crustaceans; and increase wool and/or fur production in mammals. The amount of body growth is dependent upon the sex and age of the animal species, quantity and identity of the growth hormone releasing compound
5 being administered, route of administration, and the like.

The novel polypeptide compounds of this invention can be synthesized according to the usual methods of solution and solid phase peptide chemistry, or by
10 classical methods known in the art. The solid-phase synthesis is commenced from the C-terminal end of the peptide. A suitable starting material can be prepared, for instance, by attaching the required protected alpha-amino acid to a chloromethylated
15 resin, a hydroxymethyl resin, a benzhydrylamine (BHA) resin, or a para-methyl-benzylhydrylamine (p-Me-BHA) resin. One such chloromethyl resin is sold under the tradename BIOBEADS SX-1 by Bio Rad Laboratories, Richmond, Calif. The preparation of the hydroxy-
20 methyl resin is described by Bodansky et al., Chem. Ind. (London) 38, 1597 (1966). The BHA resin has been described by Pietta and Marshall, Chem. Commn., 650 (1970) and is commercially available from Peninsula Laboratories, Inc., Belmont, California,
25 or Beckman Instruments, Inc., Palo Alto, California, in the hydrochloric form thereof (BHA·HCl).

After the initial attachment, the alpha-amino protecting group can be removed by a choice of acidic reagents, including trifluoroacetic acid (TFA) or
30 hydrochloric acid (HCl) solutions in organic solvents at room temperature. After removal of the alpha-amino protecting group, the remaining protected amino acids can be coupled stepwise in the desired order. Each protected amino acid can be generally reacted in
35 about a 3-fold excess using an appropriate carboxyl

- 10 -

group activator such as dicyclohexylcarbodiimide (DCC) in solution, for example, in methylene chloride (CH_2Cl_2) or dimethylformamide (DMF) and mixtures thereof.

5 After the desired amino acid sequence has been completed, the desired peptide can be cleaved from the resin support by treatment with a reagent such as hydrogen fluoride (HF) which not only cleaves the peptide from the resin, but also cleaves most
10 commonly used side-chain protecting groups. When a chloromethyl resin or hydroxymethyl resin is used, HF treatment results in the formation of the free peptide acid. When the BHA or p-Me-BHA resin is used, HF treatment results directly in free peptide
15 amides.

The solid-phase procedure discussed above is well known in the art and has been described by Stewart and Young, Solid Phase Peptide Synthesis: (Freeman and Co., San Francisco, 1969).

20 Some of the well known solution methods which can be employed to synthesize the peptide moieties of the instant invention are set forth in Bodansky et al., Peptide Synthesis, 2nd Edition, John Wiley & Sons, New York, N.Y. 1976.

25 In accordance with another embodiment of the present invention, a method is provided for promoting release and/or elevation of growth hormone levels in the blood of an animal. Said method comprises administering to an animal an effective dose of at
30 least one of the above-described polypeptides.

The compounds of this invention can be administered by oral, parenteral (intramuscular (i.m.), intraperitoneal (i.p.), intravenous (i.v.) or subcutaneous (s.c.) injection), nasal, vaginal,
35 rectal or sublingual routes of administration and can

- 11 -

be formulated in dosage forms appropriate for each route of administration.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and
5 granules. In such solid dosage forms, the active compound is mixed with at least one inert carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than inert diluents,
10 e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

15 Liquid dosage forms for oral administration include emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides, such inert diluents, compositions can also include adjuvants,
20 such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

Preparations according to this invention for parenteral administration include sterile aqueous or
25 non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such
30 dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the composi-
35 tions, by irradiating the compositions, or by heating

- 12 -

the compositions. They can also be manufactured in a medium of sterile water, or some other sterile injectable medium immediately before use.

As previously disclosed in our copending applications Serial No. 861,968 and S.N. 37,275, the novel compounds of the present invention are also useful when administered in combination with growth hormone releasing hormone (i.e., naturally occurring growth hormone releasing hormone, analogs and functional equivalents thereof), as well as in combination with growth hormone releasing peptides which act on the hypothalamus (rather than acting on the pituitary gland) and thyrotropin releasing hormone (TRH). Such combinations represent an especially preferred means to administer the growth hormone releasing peptides of the present invention. For further detail on the administration of combinations of growth hormone releasing peptides, those of skill in the art are referred to the above-cited application.

The amount of polypeptide or combination of polypeptides of the present invention administered will vary depending upon the particular animal treated, its age and sex, the desired therapeutic affect, the route of administration and which polypeptide or combination of polypeptides are employed. In all instances, however, a dosage effective to promote release and elevation of growth hormone level in the blood of the recipient animal is used. Ordinarily, this dosage level falls in the range of between about 0.1 μ g up to 10 mg of total polypeptide per kg of body weight. In general, the administration of combinations of growth hormone releasing peptides will allow for lower doses of the individual growth hormone releasing compounds to be employed relative to the dosage levels required for individual growth

- 13 -

hormone releasing compounds in order to obtain a similar response, due to the synergistic effect of the combination.

Also included within the scope of the present invention are compositions comprising, as an active ingredient, the organic and inorganic addition salts of the above described polypeptides optionally thereof, in association with a carrier, diluent, slow release matrix, or coating.

The organic or inorganic addition salts of the growth hormone releasing compounds and combinations thereof contemplated to be within the scope of the present invention include salts of such organic moieties as acetate, trifluoroacetate, oxalate, valerate, oleate, laurate, benzoate, lactate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthalate, and the like; and such inorganic moieties as Group I (i.e., alkali metal salts), Group II (i.e., alkaline earth metal salts) ammonium and protamine salts, zinc, iron, and the like with counterions such as the chloride, bromide, sulfate, phosphate and the like, as well as the organic moieties referred to above.

Pharmaceutically acceptable salts are preferred when administration to human subjects is contemplated. Such salts include the non-toxic alkali metal, alkaline earth metal and ammonium salts commonly used in the pharmaceutical industry including the sodium, potassium, lithium, calcium, magnesium, barium, ammonium and protamine salts which are prepared by methods well known in the art. The term also includes non-toxic acid addition salts which are generally prepared by reacting the compounds of this invention with a suitable organic or inorganic acid. Representative salts include the

- 14 -

hydrochloride, hydrobromide, sulfate, bisulfate, acetate, oxalate, valerate, oleate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napsylate, and the like.

The invention will now be described in greater detail by reference to the following non-limiting examples.

10 EXAMPLE 1 - Synthesis of the Growth Hormone Releasing Peptides

Paramethyl benzhydrylamine hydrochloride (p-Me-BHA·HCl) resin is placed in a reaction vessel on a commercially available automated peptide synthesizer. The resin is substituted with free amine up to a loading of about 5 mmoles per gram. The compounds are prepared by coupling individual amino acids starting at the carboxy terminus of the peptide sequence using an appropriate activating agent, such as N,N'-dicyclohexylcarbodiimide (DCC). The alpha amine of individual amino acids are protected, for example, as the t-butyloxycarbonyl derivative (t-Boc) and the reactive side chain functionalities are protected as outlined in Table 1.

- 15 -

Table 1Side Chain Protecting Groups Suitable for
Solid Phase Peptide Synthesis

	Arginine:	N ^g -Tosyl
5	Aspartic Acid:	O-Benzyl
	Cysteine:	S-para-Methylbenzyl
	Glutamic Acid:	O-Benzyl
	Histidine:	N ^{im} -Tosyl
	Lysine:	N ^c -2,4-Dichlorobenzoyloxycarbonyl
10	Methionine:	S-Sulfoxide
	Serine:	O-Benzyl
	Threonine:	O-Benzyl
	Tryptophan:	N ⁱⁿ -Formyl
	Tyrosine:	O-2,6-Dichlorobenzyl

- 15 Prior to incorporation of the initial amino acid, the resin is agitated three times (about one minute each) with dichloromethane (CH₂Cl₂; about 10 ml/gm of resin), neutralized with three agitations (about two minutes each) of N,N-diisopropylethyl-
- 20 amine (DIEA) in dichloromethane (10:90; about 10 ml/gm of resin) and agitated three times (about one minute each) with dichloromethane (about 10 ml/gm of resin). The initial and each of the subsequent amino acids are coupled to the resin using a preformed
- 25 symmetrical anhydride using about 3.0 times the total amount of the binding capacity of the resin of a suitably protected amino acid and about 1.5 times the total amount of the binding capacity of the resin of DCC in an appropriate amount of dichloromethane. For
- 30 amino acids with a low dichloromethane solubility, N,N-dimethylformamide (DMF) is added to achieve a homogenous solution. Generally, the symmetrical anhydride is prepared up to 30 minutes prior to introduction into the reaction vessel at room

- 16 -

temperature or below. The dicyclohexylurea that forms upon preparation of the symmetrical anhydride is removed via gravity filtration of the solution into the reaction vessel. Progress of the coupling
5 of the amino acid to the resin is commonly monitored via a color test using a reagent such as ninhydrin (which reacts with primary and secondary amines. Upon complete coupling of the protected amino acid to the resin (>99%), the alpha amine protecting group
10 is removed by a series of acidic reagents. A commonly used reagent consists of a solution of trifluoroacetic acid (TFA), and anisole in dichloromethane (45:2:53). The complete procedure for incorporation of each individual amino acid
15 residue onto the resin is outlined in Table 2.

- 17 -

TABLE 2

Procedure for Incorporation of Individual Amino
Acids onto a Resin

	<u>Reagent</u>	<u>Agitations</u>	<u>Time/Agitation</u>
5	1. Dichloromethane	3	1 min.
	2. TFA, Anisole, Dichloromethane (45:2:53)	1	2 min.
	3. TFA, Anisole, Dichloromethane (45:2:53)	1	20 min.
10	4. Dichloromethane	3	1 min.
	5. DIEA, Dichloromethane (10:90)	3	2 min.
	6. Dichloromethane	3	1 min.
15	7. Preformed symmetrical anhydride	1	15-120 min.*
	8. Dichloromethane	3	1 min.
	9. iso-Propanol	3	1 min.
	10. Dichloromethane	3	1 min.
20	11. Monitor progress of the coupling reaction**		
	12. Repeat Steps 1-12 for each individual amino acid		

*Coupling time depends upon the individual amino acid.

25 **The extent of coupling can be generally monitored by a color test. If the coupling is incomplete, the same amino acid can be recoupled by repeating Steps 7-11. If the coupling is complete the next amino acid can be coupled.

- 18 -

EXAMPLE 2 - In Vivo GH Release in Rats

Immature female Sprague-Dawley rats were obtained from the Charles River Laboratories (Wilmington, MA). After arrival they were housed at 25° C with a 14:10 hr light:dark cycle. Water and Purina rat chow were available ad libitum. Pups were kept with their mothers until 21 days of age.

Normal saline with 0.1% gelatin was the vehicle for intravenous (i.v.) injections of the peptides. In some experiments in which the peptides were very insoluble, DMSO was used to dissolve the compounds, with dilutions then being made to the specified concentration with normal saline with 0.1% gelatin (compounds for which DMSO was needed to effect solution are so noted in the Tables). The unanesthetized rats, weighing 55-65 grams, were injected i.v. with the quantity of growth hormone releasing compounds indicated in Tables 3-4. Injection was made as a 0.2 ml solution via the tail vein. All animals were sacrificed by guillotine 10 min after the final test injection (see Table 3) or 30 minutes after the final test injection (see Table 4). Trunk blood for the determination of blood GH levels was collected following decapitation. After allowing the blood to clot, it was centrifuged and the serum was separated from the clot. Serum was kept frozen until the day of sampling for radio-immunoassay (RIA) determination of growth hormone levels according to the following procedure, as developed by the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases (NIADDK).

Reagents are generally added to the RIA analysis tubes at a single sitting, at refrigerator temperature (about 4°C) in the following sequence:

- 19 -

- (a) buffer,
- (b) "cold" (i.e., non-radioactive) standard or unknown serum sample to be analyzed,
- (c) radio-iodinated growth hormone antigen, and
- 5 (d) growth hormone antiserum.

Reagent addition is generally carried out so that there is achieved a final RIA tube dilution of about 1:30,000 (antiserum to total liquid volume; vol:vol).

- 10 The mixed reagents are then typically incubated at room temperature (about 25°C) for about 24 hours prior to addition of a second antibody (e.g., goat or rabbit anti-monkey gamma globulin serum) which binds to and causes precipitation of the complexed growth
- 15 hormone antiserum. Precipitated contents of the RIA tubes are then analyzed for the number of counts in a specified period of time in a gamma scintillation counter. A standard curve is prepared by plotting number of radioactive counts versus growth hormone
- 20 (GH) level. GH levels of unknowns are then determined by reference to the standard curve.

Serum GH was measured by RIA with reagents provided by the National Hormone and Pituitary Program.

- 25 Serum levels in Tables 3 and 4 are recorded in ng/ml in terms of the rat GH standard of 0.61 International Units/mg (IU/mg). Data is recorded as the mean +/- standard error of the mean (SEM). Statistical analysis was performed with Student's
- 30 t-test. In Tables 3 and 4 the results shown are the average of studies with six rats.

Table 3
In Vivo GH Release (ng/ml) Promoted by Growth Hormone Releasing Compounds
(Animals Sacrificed 10 Minutes After Final Injection)

Number	Column A Growth Hormone Releasing Compounds	Total Dose (μ g)	Control GH ng/ml	GH Released by Compound in Column A ng/ml
8937	(beta)Ala-His-DTrp-Ala- Trp-DPhe-Lys-NH ₂	10	10 \pm 1.4	32 \pm 4
8588	Ala-His-DPal-Ala-Trp- DPhe-Lys-NH ₂	100	8 \pm .8	19 \pm 5
8323	Ala-His-DTrp-Ala-Pal- DPhe-Lys-NH ₂	100	3 \pm 0.5	18 \pm 1
9308	Ala-Cys-DTrp-Ala-Trp- DPhe-Lys-Cys-NH ₂ *	10	14 \pm 2.0	10 \pm 1
9887	Ala-His-DTrp-Ala-Trp- DPgl-Lys-NH ₂ *	10	13 \pm 1.0	11 \pm 1
9090	Ala-His-DTrp-DLys-Trp- DPhe-Lys-NH ₂ *	10	7 \pm 2.0	14 \pm 3
10265	Ala-His-DArg-Ala-Trp- DPhe-Lys-NH ₂ *	10	13 \pm 2	14 \pm 2
10351	DDopa-Ala-His-DTrp-Ala- Trp-DPhe-Lys-NH ₂ *	10	12 \pm 2	13 \pm 2
8758	Cys-Ala-His-DTrp-Ala- Trp-DPhe-Lys-Cys-NH ₂ **	10	8.0 \pm 2.0	37 \pm 8
8758	Cys-Ala-His-DTrp-Ala- Trp-DPhe-Lys-Cys-NH ₂ **	10	14.0 \pm 2.0	26 \pm 9
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	3.0 \pm 0.5	93 \pm 30

*compounds so designated are structurally similar to the growth hormone releasing compounds according to the invention, but do not display the ability to promote the release of growth hormone promoted by invention compounds.

**contains cyclic disulfide bridge between Cys groups

Table 3
In Vivo GH Release (ng/ml) Promoted by Growth Hormone Releasing Compounds
(Animals Sacrificed 10 Minutes After Final Injection)

Number	Column A Growth Hormone Releasing Compounds	Total Dose (μ g)	Control GH ng/ml	GH Released by Compound in Column A ng/ml
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	17.0 \pm 3.0	129 \pm 46
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	10.0 \pm 1.4	52 \pm 8
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	7.0 \pm 2.0	54 \pm 7
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	12.0 \pm 1.0	72 \pm 9
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	14.0 \pm 2.0	119 \pm 28
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	7.3 \pm 2.0	55 \pm 13
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	2.2 \pm 0.6	152 \pm 40
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	14.0 \pm 1.0	132 \pm 36
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	9.0 \pm 4.0	105 \pm 37
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	7.0 \pm 0.6	117 \pm 36
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	2.0 \pm 0.2	115 \pm 50
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	6.0 \pm 0.7	169 \pm 60

- 22 -

Table 3
In Vivo GH Release (ng/ml) Promoted by Growth Hormone Releasing Compounds
(Animals Sacrificed 10 Minutes After Final Injection)

Number	Column A Growth Hormone Releasing Compounds	Total Dose (μ g)	Control GH ng/ml	GH Released by Compound in Column A ng/ml
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	9.0 \pm 1.0	210 \pm 42
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	18.0 \pm 3.0	255 \pm 73
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	10.0 \pm 1.0	315 \pm 65
8114	Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	30.0 \pm 1.0	114 \pm 20
8866	Tyr-Ala-Gly-Thr-Ala-His- DTrp-Ala-Trp-DPhe-Lys-NH ₂	10	8.0 \pm 2.0	177 \pm 38
8866	Tyr-Ala-Gly-Thr-Ala-His- DTrp-Ala-Trp-DPhe-Lys-NH ₂	30	8.0 \pm 2.0	144 \pm 38
8866	Tyr-Ala-Gly-Thr-Ala-His- DTrp-Ala-Trp-DPhe-Lys-NH ₂	10	14.0 \pm 1.0	292 \pm 42
9106	Tyr-DAla-Phe-Gly-Ala-His- DTrp-Ala-Trp-DPhe-Lys-NH ₂	100	14.0 \pm 1.0	116 \pm 42
9216	Tyr-DAla-Gly-Phe-Ala-His- DTrp-Ala-Trp-DPhe-Lys-NH ₂	30	12.0 \pm 1.0	46 \pm 12
9216	Tyr-DAla-Gly-Phe-Ala-His- DTrp-Ala-Trp-DPhe-Lys-NH ₂	100	14.0 \pm 1.0	196 \pm 43
8938	His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	3.0 \pm 0.5	70 \pm 29
9036	His-DTrp-Ala-Trp-DPhe-Lys- Ala-Tyr-NH ₂	10	10.0 \pm 1.0	52 \pm 7
9020	Abu-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	10	18.0 \pm 11.0	85 \pm 24

Table 3
In Vivo GH Release (ng/ml) Promoted by Growth Hormone Releasing Compounds
(Animals Sacrificed 10 Minutes After Final Injection)

Number	Column A Growth Hormone Releasing Compounds	Total Dose (μ g)	Control GH ng/ml	GH Released by Compound in Column A ng/ml
9868	DOPA-Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	13.0 \pm 1.0	123 \pm 30
10276	Leu-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	10	13.0 \pm 2	190 \pm 58
10276	Leu-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	10	13.0 \pm 1.0	74 \pm 25
10321	Val-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	10	13.0 \pm 2	137 \pm 28
10337	Phe-Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	12.0 \pm 2.0	68 \pm 11
10337	Phe-Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	14.0 \pm 2.0	132 \pm 45
10391	Ala-His-DTrp-Ala-Trp-DPhe- Lys-Gly-Tyr-NH ₂ (a)	10	12.0 \pm 2.0	36 \pm 6
10391	Ala-His-DTrp-Ala-Trp-DPhe- Lys-Gly-Tyr-NH ₂ (a)	10	14.0 \pm 2.0	155 \pm 59
10321	Val-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	1	5.0 \pm 0.4	11 \pm 2
10321	Val-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	3	5.0 \pm 0.4	129 \pm 13
10321	Val-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	10	5.0 \pm 0.4	68 \pm 29
10855	Ala-His-(formyl)DTrp-Ala- Trp-DPhe-Lys-NH ₂	10	6.0 \pm 1.0	19 \pm 6

(a) Compound initially dissolved in 10 mM acetic acid

Table 3
In Vivo GH Release (ng/ml) Promoted by Growth Hormone Releasing Compounds
(Animals Sacrificed 10 Minutes After Final Injection)

Number	Column A Growth Hormone Releasing Compounds	Total Dose (μ g)	Control GH ng/ml	GH Released by Compound in Column A ng/ml
10814	Dopa-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	3	6.0 \pm 1.0	67 \pm 17
10814	Dopa-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	10	6.0 \pm 1.0	76 \pm 20
10957	Trp-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂ (b)	10	7.0 \pm 1.0	127 \pm 23
10957	Trp-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂ (b)	30	7.0 \pm 1.0	268 \pm 58
10873	Met-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂ (b)	10	7.0 \pm 1.0	65 \pm 18
10873	Met-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂ (b)	30	7.0 \pm 1.0	161 \pm 47
10973	Ala-His-DTrp-Ser-Trp-DPhe- Lys-NH ₂ (b)	10	7.0 \pm 0.5	30 \pm 7
11009	Lys-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂ (b)	3	5.0 \pm 0.4	57 \pm 9
11009	Lys-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂ (b)	10	5.0 \pm 0.4	217 \pm 64
11012	Asp-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	10	7.0 \pm 0.5	128 \pm 48
11012	Asp-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	10	12.0 \pm 0.5	107 \pm 26
18988	Met(O)-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	14.0 \pm 0.5	65 \pm 17
18988	Met(O)-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	5.0 \pm 0.4	90 \pm 25

(b) Invention compound initially dissolved in DMSO, then diluted as described in the text.

Table 3
In Vivo GH Release (ng/ml) Promoted by Growth Hormone Releasing Compounds
 (Animals Sacrificed 10 Minutes After Final Injection)

<u>Number</u>	<u>Column A Growth Hormone Releasing Compounds</u>	<u>Total Dose (μg)</u>	<u>Control GH ng/ml</u>	<u>GH Released by Compound in Column A ng/ml</u>
11553	Tyr-Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	6.5 \pm 0.5	170 \pm 38
11561	Lys-His-DTrp-Ala-Trp-DPhe- Asp-NH ₂	3	8.0 \pm 1.0	9 \pm 1
11561	Lys-His-DTrp-Ala-Trp-DPhe- Asp-NH ₂	10	8.0 \pm 1.0	11 \pm 1
11562	Arg-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	3	8.0 \pm 1.0	50 \pm 17
11562	Arg-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	10	8.0 \pm 1.0	87 \pm 27
11603	Lys-Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	3	16.0 \pm 3.0	41 \pm 5
11603	Lys-Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	10	16.0 \pm 3.0	82 \pm 19
11603	Lys-Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	30	16.0 \pm 3.0	135 \pm 38
11839	Ala-His-DTrp-Ala-Trp-DPhe- iLys-NH ₂	3	12.0 \pm 3.0	30 \pm 7
11839	Ala-His-DTrp-Ala-Trp-DPhe- iLys-NH ₂	10	12.0 \pm 3.0	59 \pm 18
11839	Ala-His-DTrp-Ala-Trp-DPhe- iLys-NH ₂	30	12.0 \pm 3.0	246 \pm 63
12392	His-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	10	10.0 \pm 0	479 \pm 64

- 26 -

Table 4
In Vivo GH Release (ng/ml) Promoted by Growth Hormone Releasing Compounds
(Animals Sacrificed 30 Minutes After Final Injection)

Number	Column A Growth Hormone Releasing Compounds	Total Dose, (ng)	Control GH ng/ml	GH Released by Compound in Column A, ng/ml
8114	Ala-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	NA*	69 ± 6
8114	Ala-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	5 ± 2	46 ± 7
8114	Ala-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	8 ± 3	94 ± 27
11603	Lys-Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	20	NA	105 ± 14
11009	Lys-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	NA	131 ± 26
11009	Lys-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	5 ± 2	35 ± 9
10337	Phe-Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	20	NA	102 ± 9
10814	DOPA-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	NA	105 ± 10
10765	DOPA-Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	20	NA	30 ± 7
10276	Leu-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	NA	98 ± 29
10321	Val-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	NA	156 ± 39
10321	Val-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	8 ± 3	93 ± 25
10021	Asp-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	NA	135 ± 17
10957	Trp-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	NA	134 ± 38

*NA = Not Available

- 27 -

Table 4
In Vivo GH Release (ng/ml) Promoted by Growth Hormone Releasing Compounds
 (Animals Sacrificed 30 Minutes After Final Injection)

<u>Number</u>	<u>Column A Growth Hormone Releasing Compounds</u>	<u>Total Dose, (ng)</u>	<u>Control GH ng/ml</u>	<u>GH Released by Compound in Column A, ng/ml</u>
10957	Trp-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	5 ± 2	66 ± 16
10873	Met-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	NA*	159 ± 4
10873	Met-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	5 ± 2	46 ± 15
10873	Met-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	8 ± 3	95 ± 20
9020	Abu-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	NA	72 ± 8
0933	Ala-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	NA	86 ± 19
10391	Ala-His-DTrp-Ala-Trp-DPhe- Lys-Gly-Tyr-NH ₂	20	6 ± 1	47 ± 8
8758	Cys-Ala-His-DTrp-Ala-Trp- DPhe-Lys-Cys-NH ₂ (cyclic disulfide)	20	6 ± 1	52 ± 7
8866	Tyr-Ala-Gly-Thr-Ala-His- DTrp-Ala-Trp-DPhe-Lys- NH ₂	20	6 ± 1	32 ± 8
11553	Tyr-Ala-His-DTrp-Ala-Trp- DPhe-Lys-NH ₂	20	6 ± 1	59 ± 12
11012	Asp-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	5 ± 2	74 ± 15
12392	His-His-DTrp-Ala-Trp-DPhe- Lys-NH ₂	20	5 ± 2	100 ± 16

*NA = Not Available

- 28 -

In Tables 3 and 4, compounds of the invention are shown to promote the release and elevation of growth hormone levels in the blood of rats to which such compounds have been administered. These results are
5 surprising in view of the lack of growth hormone releasing activity displayed by several strikingly similar compounds which are also included in Table 3.

Data in Table 4 further demonstrate the prolonged
10 period (30 minutes versus 10 minutes for data in Table 3) over which compounds of the invention are effective at promoting the release and elevation of growth hormone levels.

15 EXAMPLE 3 - In Vivo Growth Hormone Release Study - Lambs

Female lambs (20-28 kg) were housed in individual cages in a constant temperature room at 24°C with 12h-12h light-dark cycle. The lambs were fed a diet containing grade 2 corn, soybean meal, orchard
20 grass hay, molasses and premix.

Various doses of the compound Ala-His-DTrp-Ala-Trp-DPhe-Lys-NH₂ (Compound #8114) were dissolved in 200 µl of 10mM acetic acid and brought to 5 ml with phosphate buffered saline (PBS). Lambs were
25 catheterized via the jugular vein. Intravenous infusions were performed by using a multichannel infusion pump (Model 600-900, Harvard Apparatus Co., Inc., Dover, Mass.) preset at a flow rate of 1.36 ml/min. Sampling of blood was performed every 20
30 minutes starting 1 hour prior to treatment and continuing until 1 hour after treatment. Additional samples were taken at -10 min., +5 min. and +10 min. Blood samples were drawn and deposited into EDTA-treated tubes for plasma preparation. EDTA

- 29 -

treated plasma was analyzed for GH using a standard double antibody RIA, according to the following procedure:

- 30 -

PROCEDURE FOR LAMB GROWTH
HORMONE RADIOIMMUNMOASSAY

Reagents

- 5 1. Phosphosaline Buffer (0.15 M NaCl-0.012 M
Phosphate) (PSB):

Add 5.14 gm $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ (monobasic) and
26.6 gm sodium chloride to 2.95 liters distilled
water.

- 10 Add 2.0 M sodium hydroxide dropwise to bring pH
to 7.5.

Add 3 ml merthiolate as preservative.

Bring total volume to 3.0 liters.

Store at 4°C.

- 15 2. Phosphosaline Buffer With 1% Bovine Serum Albumin
(PBSA):

Dilute commercially available 30% solution of
bovine serum albumin (BSA) thirtyfold with
phosphosaline buffer (PSB).

Store at 4°C and use without further dilution.

- 20 3. Ovine Growth Hormone Antiserum (rabbit):

Stored frozen at 1:10 dilution (as obtained).

- 31 -

Working dilution is 1:20,000. Prepare only enough dilution to last one week. Store at 4°C.

4. Ovine Growth Hormone:

5 Prepare and store frozen in vials (2.5 µg/0.5 ml PBSA/vial).

5. Radioiodinated Ovine Growth Hormone ..
(Approximately 10,000 cpm/100 µl).

6. Goat Anti-Rabbit Gamma Globulin (suggested
10 sources, Antibodies, Inc., Cambridge Medical
Diagnostics, Inc.)

Stored frozen in 1 ml aliquots.

7. 6% PEG in PSB:

Weight 6.0 gm Polyethylene Glycol 6000.

Dilute to 100 ml in PSB (see 1).

15 Store at 4°C.

8. 0.05 M EDTA:

Weight 1.9 gm (Ethylenedinitrilo)-tetraacetic
Acid Tetrasodium Salt.

Dilute to 100 ml in PSB (see 1).

20 Adjust pH to 7.5 with NaOH.

Store at 4°C.

- 32 -

9. Normal Rabbit Serum:

Store frozen in 1.0 ml aliquots.

10. Normal Rabbit Serum:EDTA (1:400) (NRS:EDTA):

5 Dilute 0.25 ml NRS to 100 ml with 0.05 M EDTA
(see 8);

Store at 4°C.

Assay Procedure (for 250 Tubes)DAY 1

1. Label 12 x 75 mm glass tubes as follows:

10 Tubes 1-2 (to be used to measure nonspecific
binding NSB).

Tubes 3-4 (to be used to measure maximum binding
 B_0).

Tubes 5-6 (to be used to measure total counts).

15 Tubes 7-18 (to be used for standards A-F).

Starting with tube 19, two tubes are
consecutively numbered for each control or
sample.

20 2. Add 4.5 ml PBSA to 2.5 µg/0.5 ml stock ovine
growth hormone. (The concentration is now 500
ng/ml)

- 33 -

Continue to dilute standards as follows:

- A - 0.25 ng/100 μ l ---> dilute D 1/10
(100 μ l + 900 μ l PBSA)
- 5 B - 0.5 ng/100 μ l ---> dilute E 1/10
(100 μ l + 900 μ l PBSA)
- C - 1 ng/100 μ l ---> dilute F 1/10
(100 μ l + 900 μ l PBSA)
- D - 2.5 ng/100 μ l ---> dilute stock 1/20
(50 μ l + 950 μ l PBSA)
- 10 E - 5 ng/100 μ l ---> dilute stock 1/10
(100 μ l + 900 μ l PBSA)
- F - 10 ng/100 μ l ---> dilute stock 1/5
(200 μ l + 800 μ l PBSA)
- 15 3. Dilute ovine growth hormone antiserum (1:10
dilution) to 1:20,000 (25 μ l antiserum + 49.98
ml 1:400 NRS:EDTA).
4. Add 200 μ l NRS:EDTA + 500 μ l PBSA to tubes 1
and 2. (to determine NSB).
- 20 5. Add 500 μ l PBSA to tubes 3 and 4. (to
determine B_0).
6. Add 100 μ l of Standards A through F, controls
or samples as follows:

- 34 -

	<u>Tube No.</u>	<u>Standards, Controls or Samples</u>
	7,8	A
	9,10	B
	11,12	C
5	13,14	D
	15,16	E
	17,18	F
	Sample	Unknown

- 10 7. Add 400 μ l PBSA to standards A-F and all samples.
8. Add 200 μ l of diluted ovine growth hormone antiserum to all tubes except NSB (1 and 2) and total counts (5 and 6).
- 15 9. Vortex tubes, cover tubes and incubate at 40°C for 20 hours.

DAY 2

- 20 10. Add 100 μ l of radioiodinated ovine growth hormone to all tubes. (Approximately 10,000 cpm/100 μ l.) Vortex tubes and incubate at 4°C for 20 hours.

DAY 3

11. Dilute goat anti-rabbit gamma globulin to 1:10 or as stated on container with PBSA.
- 25 Add 200 μ l of diluted goat anti-rabbit gamma globulin to all tubes (except tubes 5 and 6).

- 35 -

Vortex tubes and incubate at room temperature for 15 minutes.

12. Add 1 ml 6% PEG in PSB to all tubes (except tubes 5 and 6). Vortex and centrifuge at 1500-1600 g for 25 minutes.

13. Measure precipitate for radioactivity counts using an LKB Model 1275 gamma-scintillation counter.

Iodination grade ovine GH was obtained from the National Pituitary Center, and was used for iodination (Chloramine T method) and standard. The anti-ovine GH serum was also obtained from the National Pituitary Center. The results are presented in Table 5. The amount of growth hormone released is expressed as the maximum height of the growth hormone peak and the area under the growth hormone peak measured for one hour after the administration of Compound #8114.

- 36 -

Table 5

Effects of Compound #8114 on Plasma Growth
Hormone Concentrations in Lambs

5	<u>Treatment</u>	-GH Area Under Curve, ng-min/mL; (GH Maximum Peak Height, ng/ml)- Dose*		
		<u>1 µg/kg</u>	<u>10 µg/kg</u>	<u>30 µg/kg</u>
	Phosphate buffered saline (control)	40 (3)	73 (3)	36 (2)
	Compound #8114	67 (2)	228 (7)	1,086 (38)

10 *Dose is the amount of the trifluoroacetic acid salt(s)
of Compound #8114 administered. The actual percent
peptide content of Compound #8114 administered can be
determined by such well known procedures as elemental
analysis or amino acid analysis.

15 In Table 5, Compound #8114 is shown to promote
the release and elevation of growth hormone levels in
the blood of lambs to which the compound has been
administered. The increase in blood growth hormone
levels is also shown to be related to the dosage of
20 Compound #8114.

- 37 -

EXAMPLE 4 - In Vivo Growth Hormone Release Study -
Beef Calves

Female beef calves (151-191 kg) were housed in individual cages in a constant temperature room at 24°C with 12h-12h light-dark cycle. The beef calves were fed a diet containing cracked corn, corn silage, soybean meal, alfalfa hay, molasses and premix.

Various doses of the compound Ala-His-DTrp-Ala-Trp-DPhe-Lys-NH₂ (Compound #8114) were dissolved in 200 µl of 10 mM acetic acid and brought to 5 ml with phosphate buffered saline (PBS). The calves were catheterized via the jugular vein. Intravenous infusions were performed by using a multichannel infusion pump (Model 600-900, Harvard Apparatus Co., Inc., Dover, Mass.) preset at a flow rate of 1.36 ml/min. Sampling of blood was performed every 20 minutes starting one hour prior to treatment and continuing until three hours after treatment. Additional samples were taken at -10 min., +5 min., and +10 min. Blood samples were drawn and deposited into EDTA-treated tubes for plasma preparation. EDTA treated plasma was analyzed for GH using a standard double antibody RIA in accordance with the procedure set forth above. Iodination grade bovine growth hormone (bGH) was obtained from the National Pituitary Center, and was used for iodination and standard. The anti-bGH serum was also obtained from the National Pituitary Center.

Results are presented in Table 6. The amount of growth hormone released is expressed as the maximum height of the growth hormone peak and the area under the growth hormone peak measured for three hours after the administration of #8114.

- 38 -

Table 6

Effects of Compound #8114 on Plasma Growth Hormone
Concentrations in Beef Cattle

5		-GH Area Under Curve, ng-min/ml; (GH Maximum Peak Height, ng/ml)- Dose*		
	<u>Treatment</u>	<u>1 µg/kg</u>	<u>10 µg/kg</u>	<u>30 µg/kg</u>
	Phosphate buffered saline	412 (12)	472 (11)	703 (20)
10	Compound #8114	897 (16)	2300 (66)	4811 (99)

*Dose is the amount of the trifluoroacetic acid salt(s)
of Compound #8114 administered. The actual percent
peptide content of Compound #8114 administered can be
determined by such well known procedures as elemental
analysis or amino acid analysis.

- 39 -

In Table 6, Compound #8114 is shown to promote the release and elevation of growth hormone levels in the blood of beef calves to which the compound has been administered. The increase in blood growth hormone levels is also shown to be related to the dosage of Compound #8114.

EXAMPLE 5 - In Vivo Growth Hormone Release Study - Cows

Four non-lactating Holstein cows (mean body weight 543 kg) were housed outside in pasture and brought into the large animal laboratory for experimental studies in conventional stanchions. Cow diet was hay, grass and 1x/day 5 lbs. of Omolene (wheat, oats, corn, soybean, molasses with vitamins and trace minerals) -- Purina. Cows were in the large animal laboratory and off grass for 1-1.5 hours before initiation of experiments. Catheters were inserted into the jugular vein for withdrawal of blood samples and IV injections of peptides. Fifteen to twenty ml of saline was flushed through the catheter after each blood drawing and a slow i.v. drip of saline was used to keep the blood from clotting in the catheter. Ten ml blood samples were collected between 9 AM and 2 PM at -40, -30, -10, 0, +5, +10, +15, +20, +25, +30, +40, +60, +90, +120, +150, +180. Normal saline with 0.1% gelatin or peptides dissolved in 0.1% gelatin saline was injected IV through the catheter at 0 time to the unanesthetized cows. The saline/peptide was infused over a 3 minute period in a 5.0 volume. The blood was allowed to clot, centrifuged and the serum separated from the clot. Serum was kept frozen until the day of sampling for radioimmunoassay (RIA) of growth hormone. Serum GH was measured by RIA with

- 40 -

reagents provided by the NIADDK. The GH levels are reported in terms of ng/ml of a bovine GH reference preparation, NIH-GH-B18, which is equivalent to 3.2 IU/mg. Data is recorded as the mean \pm the standard error of the mean (SEM). Statistical analysis was performed with the Student's t-test.

Control animals (to which no growth hormone releasing compound was administered) showed a growth hormone level of 0.17 \pm 0.19 ng/ml, while animals to which 3 μ g per kg body weight of Compound #8114 had been administered had a blood serum growth hormone level of 8.60 \pm 2.50, thus demonstrating a significant enhancement of growth hormone levels upon administration of Compound #8114.

The invention has been described in detail with particular reference to preferred embodiments thereof, but it will be understood that variations and modifications can be effected within the spirit and scope of the invention.

- 41 -

CLAIMS

We Claim:

1. A polypeptide capable of promoting the release
and elevation of growth hormone levels in the
5 blood of a recipient animal, wherein said polypeptide is selected from the group consisting of polypeptides defined by the generic structure:

X-AA1-AA2-AA3-AA4-Trp-AA6-AA7-Z,

- 10 wherein X is selected from the group consisting of H, DOPA, Lys, Phe, Tyr, Cys, Tyr-DAla-Phe-Gly, Tyr-DAla-Gly-Phe and Tyr-Ala-Gly-Thr;

AA1 is selected from the group consisting of:

all naturally occurring L-amino acids,

- 15 Met(O),

DOPA and

Abu;

- AA2 is selected from the group consisting of His
and 3(NMe)His (i.e., wherein the imidazole ring
20 is methylated at the 3-position);

- AA3 is selected from the group consisting of
DTrp, 5-fluoro-D or D/LTrp; 6-fluoro-D or D/LTrp
(i.e., wherein the indole ring is fluorinated at
the 5- or 6-position), (formyl)DTrp (i.e., DTrp
25 which is formylated at the indole nitrogen), and

- 42 -

*XTrp, wherein *XTrp is selected from the group consisting of the N-monomethylated DTrp isomers (i.e., (N^αMe)DTrp and (indole NMe)DTrp);

5 AA4 is selected from the group consisting of Ala, Gly and Ser;

AA6 is selected from the group consisting of DPhe and (NMe)DPhe;

AA7 is selected from the group consisting of Arg, iLys, Lys and Orn; and

10 Z represents the C terminal end group of said polypeptide or the C terminal amino acid(s) plus end group, wherein Z is selected from the group consisting of -CONH₂, -COOH, -COOR, -CONHR, -CONR₂, -CH₂OH and -CH₂OR, wherein R is an
15 alkyl group having 1-6 carbon atoms or an aromatic ring having up to 12 carbon atoms; and wherein Z is alternatively selected from the group consisting of -Gly-Z', -Met-Z', -Lys-Z', -Cys-Z' (when a Cys moiety is also present in the
20 1 position of the polypeptide (i.e., X or AA1 is Cys), the resulting peptide can exist in the linear form or in the cyclic form), -Gly-Tyr-Z', and -Ala-Tyr-Z', wherein Z' is selected from the group consisting of -CONH₂, -COOH, -CONHR, -COOR, -CONR₂, -CH₂OH, and -CH₂OR, wherein
25 R is as defined above;

and organic or inorganic addition salts of any of said polypeptides;

- 43 -

wherein the amino acid residue abbreviations used
are in accordance with the standard peptide
nomenclature:

	Gly	= Glycine
5	Tyr	= L-Tyrosine
	Ile	= L-Isoleucine
	Glu	= L-Glutamic Acid
	Thr	= L-Threonine
	Phe	= L-Phenylalanine
10	Ala	= L-Alanine
	Lys	= L-Lysine
	Asp	= L-Aspartic Acid
	Cys	= L-Cysteine
	Arg	= L-Arginine
15	Gln	= L-Glutamine
	Pro	= L-Proline
	Leu	= L-Leucine
	Met	= L-Methionine
	Ser	= L-Serine
20	Asn	= L-Asparagine
	His	= L-Histidine
	Trp	= L-Tryptophan
	Val	= L-Valine
	DOPA	= 3,4-L-Dihydroxyphenylalanine
25	Met(O)	= L-Methionine sulfoxide
	iLys	= N ^c -Isopropyl-L-lysine
	Abu	= alpha-L-Aminobutyric acid
	Orn	= L-Ornithine
	Pal	= 3-Pyridyl-L-alanine
30	Pgl	= L-Phenylglycine
	(beta)Ala	= beta alanine (i.e., 3-amino- propanoic acid)

All three letter amino acid abbreviations
preceded by a "D" indicate the D-configuration of
the amino acid residue.

- 44 -

2. A polypeptide in accordance with Claim 1, wherein said polypeptide is selected from the group consisting of:

- Ala-His-DTrp-Ala-Trp-DPhe-Lys-Gly-Tyr-Z';
- 5 Ala-His-(formyl)DTrp-Ala-Trp-DPhe-Lys-Z'
 (DTrp is formylated at the indole
 nitrogen);
- Ala-His-DTrp-Ser-Trp-DPhe-Lys-Z';
- Cys-Ala-His-DTrp-Ala-Trp-DPhe-Lys-Cys-Z'
- 10 (cyclic disulfide);
- Cys-Ala-His-DTrp-Ala-Trp-DPhe-Lys-Cys-Z'
- (free dithiol);
- DOPA-Ala-His-DTrp-Ala-Trp-DPhe-Lys-Z';
- His-DTrp-Ala-Trp-DPhe-Lys-Ala-Tyr-Z';
- 15 Lys-Ala-His-DTrp-Ala-Trp-DPhe-Lys-Z';
- Phe-Ala-His-DTrp-Ala-Trp-DPhe-Lys-Z';
- Tyr-Ala-Gly-Thr-Ala-His-DTrp-Ala-Trp-
 DPhe-Lys-Z';
- Tyr-Ala-His-DTrp-Ala-Trp-DPhe-Lys-Z';
- 20 Tyr-DAla-Phe-Gly-Ala-His-DTrp-Ala-Trp-DPhe-
 Lys-Z';
- Tyr-DAla-Gly-Phe-Ala-His-DTrp-Ala-Trp-DPhe-
 Lys-Z';
- Ala-His-DTrp-Ala-Trp-DPhe-iLys-NH₂;
- 25 Ala-His-DTrp-Ala-Trp-(NMe)DPhe-Lys-NH₂;
- Ala-His-*XTrp*-Ala-Trp-DPhe-Lys-Z' (*XTrp*
 is selected from the group consisting of
 5-fluoro-D or D/LTrp; 6-fluoro-D or D/LTrp
 (i.e., wherein the indole ring is
 fluorinated at the 5- or 6-position), and
 the N-monomethylated DTrp isomers, i.e.,
 (N^αMe)DTrp, and (indole NMe)DTrp);
- 30 AAl-His-DTrp-Ala-Trp-DPhe-Lys-Z';

- 45 -

wherein AAl is selected from the group consisting of:

all naturally occurring L-amino acids,

Met(O),

5 DOPA and

Abu;

wherein Z' and R are as defined above; and

organic or inorganic addition salts of any of said polypeptides.

10 3. A polypeptide in accordance with Claim 1 wherein said polypeptide is selected from the group consisting of:

DOPA-Ala-His-DTrp-Ala-Trp-DPhe-Lys-NH₂;

His-DTrp-Ala-Trp-DPhe-Lys-Ala-Tyr-NH₂;

15 Lys-Ala-His-DTrp-Ala-Trp-DPhe-Lys-NH₂;

Tyr-Ala-His-DTrp-Ala-Trp-DPhe-Lys-NH₂;

Phe-Ala-His-DTrp-Ala-Trp-DPhe-Lys-NH₂;

Ala-His-DTrp-Ala-Trp-DPhe-iLys-NH₂;

Ala-His-DTrp-Ala-Trp-(NMe)DPhe-Lys-NH₂;

20 Ala-His-DTrp-Ala-Trp-DPhe-Lys (as the free carboxylate);

AAl-His-DTrp-Ala-Trp-DPhe-Lys-NH₂;

wherein AAl is selected from the group consisting of:

25 all naturally occurring L-amino acids,

DOPA,

- 46 -

Met(O) and

Abu, and

organic or inorganic addition salts of any of said polypeptides.

- 5 4. Method of promoting the release and elevation of blood growth hormone levels in animals by administering thereto an effective amount of at least one of the polypeptides set forth in Claim 1.
- 10 5. Method of promoting the release and elevation of blood growth hormone levels in animals by administering thereto an effective amount of at least one of the polypeptides set forth in Claim 2.
- 15 6. Method of promoting the release and elevation of blood growth hormone levels in animals by administering thereto an effective amount of at least one of the polypeptides set forth in Claim 3.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁴ : C07K 7/06, 7/09 // A61K 37/43	A3	(11) International Publication Number: WO 88/ 09780 (43) International Publication Date: 15 December 1988 (15.12.88)
(21) International Application Number: PCT/US88/01947 (22) International Filing Date: 9 June 1988 (09.06.88) (31) Priority Application Number: 060,877 (32) Priority Date: 12 June 1987 (12.06.87) (33) Priority Country: US (71) Applicant: EASTMAN KODAK COMPANY [US/US]; 343 State Street, Rochester, NY 14650 (US). (72) Inventors: BOWERS, Cyril, Yarling ; 484 Audubon Street, New Orleans, LA 70118 (US). MOMANY, Frank, Alden ; 1-1 Concord Green, Concord, MA 02154 (US). CHANG, Ching, Hsong ; 16 Robin Drive, Fanwood, NJ 07023 (US). CODY, Wayne, Li- vingston ; RD 2, Box 65, Ringoes, NJ 08551 (US). HUBBS, John, Clark ; Rt. 10, Box 354, Kingsport, TN 37664 (US). FOSTER, Charles, Howard ; 1413 Do- byns Drive, Kingsport, TN 37664 (US).	(74) Agent: REITER, Stephen, E.; 343 State Street, Roches- ter, NY 14650 (US). (81) Designated States: AT (European patent), AU, BE (Eu- ropean patent), BR, CH (European patent), DE (Eu- ropean patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, NL (European patent), NO, SE (European patent), SU. Published <i>With international search report</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i> (88) Date of publication of the international search report: 12 January 1989 (12.01.89)	
(54) Title: POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY (57) Abstract Disclosed are novel polypeptide compounds which promote the release and elevation of growth hormone levels in the blood of animals. Also disclosed are methods of promoting the release and elevation of growth hormone levels in the blood of animals using the disclosed polypeptide compounds.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

INTERNATIONAL SEARCH REPORT

International Application No PCT/US88/01947

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"> IPC⁴: C 07 K 7/06, 7/08//A 61 K 37/43 </div>														
II. FIELDS SEARCHED <div style="text-align: center; margin-top: 5px;">Minimum Documentation Searched ⁷</div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr> <th style="width: 30%;">Classification System</th> <th style="width: 70%;">Classification Symbols</th> </tr> <tr> <td style="padding: 5px;">IPC⁴</td> <td style="padding: 5px;">C 07 C; C 07 K</td> </tr> </table> <div style="text-align: center; margin-top: 5px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	IPC ⁴	C 07 C; C 07 K								
Classification System	Classification Symbols													
IPC ⁴	C 07 C; C 07 K													
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category ¹⁰</th> <th style="width: 70%;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%;">Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">Endocrinology, Vol. 114, No. 5, 1984, F.A. Momany et al.: "Conformational Energy Studies and in Vitro and in Vivo Activity Data on Growth Hormone-Releasing Peptides", pages 1531-1536 --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-3</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">EP, A1, 0 018 072 (BECKMAN INSTRUMENTS, INC.,) 29 October 1980 whole document --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-3</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">WO, A1, 83/02272 (BECKMAN INSTRUMENTS, INC.:) 7 July 1983 whole document --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-3</td> </tr> </tbody> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	Endocrinology, Vol. 114, No. 5, 1984, F.A. Momany et al.: "Conformational Energy Studies and in Vitro and in Vivo Activity Data on Growth Hormone-Releasing Peptides", pages 1531-1536 --	1-3	Y	EP, A1, 0 018 072 (BECKMAN INSTRUMENTS, INC.,) 29 October 1980 whole document --	1-3	Y	WO, A1, 83/02272 (BECKMAN INSTRUMENTS, INC.:) 7 July 1983 whole document --	1-3
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
X	Endocrinology, Vol. 114, No. 5, 1984, F.A. Momany et al.: "Conformational Energy Studies and in Vitro and in Vivo Activity Data on Growth Hormone-Releasing Peptides", pages 1531-1536 --	1-3												
Y	EP, A1, 0 018 072 (BECKMAN INSTRUMENTS, INC.,) 29 October 1980 whole document --	1-3												
Y	WO, A1, 83/02272 (BECKMAN INSTRUMENTS, INC.:) 7 July 1983 whole document --	1-3												
¹⁰ Special categories of cited documents: ^{"A"} document defining the general state of the art which is not considered to be of particular relevance ^{"E"} earlier document but published on or after the international filing date ^{"L"} document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) ^{"O"} document referring to an oral disclosure, use, exhibition or other means ^{"P"} document published prior to the international filing date but later than the priority date claimed		^{"T"} later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention ^{"X"} document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step ^{"Y"} document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. ^{"&"} document member of the same patent family												
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> Date of the Actual Completion of the International Search <div style="text-align: center; margin-top: 5px;">10th October 1988</div> </td> <td style="width: 50%; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center; margin-top: 5px;">01 DEC 1988</div> </td> </tr> <tr> <td style="width: 50%; padding: 5px;"> International Searching Authority <div style="text-align: center; margin-top: 5px;">EUROPEAN PATENT OFFICE</div> </td> <td style="width: 50%; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center; margin-top: 5px;"> P.C.G. VAN DER PUTTEN </div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center; margin-top: 5px;">10th October 1988</div>	Date of Mailing of this International Search Report <div style="text-align: center; margin-top: 5px;">01 DEC 1988</div>	International Searching Authority <div style="text-align: center; margin-top: 5px;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; margin-top: 5px;"> P.C.G. VAN DER PUTTEN </div>								
Date of the Actual Completion of the International Search <div style="text-align: center; margin-top: 5px;">10th October 1988</div>	Date of Mailing of this International Search Report <div style="text-align: center; margin-top: 5px;">01 DEC 1988</div>													
International Searching Authority <div style="text-align: center; margin-top: 5px;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; margin-top: 5px;"> P.C.G. VAN DER PUTTEN </div>													

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 4-6 because they relate to subject matter not required to be searched by this Authority, namely:

Method for treatment of the human or animal body by therapy.
Rule 39(iv).

2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.

US 8801947

SA 23600

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 01/09/88
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0018072	29-10-80	US-A- 4226857	07-10-80
		JP-A- 55133344	17-10-80
		CA-A- 1175810	09-10-84
		JP-A- 59216860	06-12-84
		US-A- 4228157	14-10-80
		US-A- 4228155	14-10-80
WO-A- 8302272	07-07-83	EP-A- 0083864	20-07-83
		US-A- 4410512	18-10-83
		AU-A- 549053	09-01-86
		US-A- 4410513	18-10-83
		US-A- 4411890	25-10-83

THIS PAGE BLANK (USPTO)